BioSpace News Archive

To present recent progress of clinical pipeline at the H.C. Wainwright Bioconnect Conference Will participate in LifeSci Advisors’ 10 th Annual LifeSci Advisors Corporate Access Event 2021 Will participate in Edison’s Open House – Global Healthcare 2021 Will present and participate at ACCESS CHINA Forum @JPM Week 2021 All virtual events during three consecutive weeks in January

Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically improve the lives of patients with neurodegenerative diseases, announced today that it has agreed to sell its stake in Arvelle Therapeutics to Angelini Pharma, as part of that company’s cash acquisition of 100% of the stock of Arvelle Therapeutics for up to $960 million.

Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for persons living with an autoimmune disease, requiring an organ or cell-based transplant, or living with amyotrophic lateral sclerosis (ALS), today provided a corporate update and offered its outlook for 2021 and beyond.

Poseida Therapeutics, Inc. (NASDAQ: PSTX), a clinical-stage biopharmaceutical company utilizing proprietary gene engineering platform technologies to create cell and gene therapeutics with the capacity to cure, today announced that Eric Ostertag , M.D., Ph.D., Poseida Therapeutics’ Chief Executive Officer, will participate in a pre-reco

Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that John P. Butler , President and Chief Executive Officer, will present virtually at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13 , a

Insmed Incorporated (Nasdaq: INSM), today announced that the first patient was dosed in late December, 2020, in the frontline clinical trial program of ARIKAYCE® (amikacin liposome inhalation suspension) in patients with nontuberculous mycobacterial (NTM) lung disease caused by Mycobacterium avium complex (MAC)

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer brands and a top supplier of sustainable and natural ingredients, today announced that it will be launching its Biossance TM Clean Beauty skincare brand into the Greater China market throug

INOVIO (NASDAQ: INO), and Advaccine Biopharmaceuticals Suzhou Co., Ltd. (“Advaccine”), today announced that they have entered into a collaboration and license agreement for COVID-19 DNA vaccine candidate INO-4800.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that in December it recommenced patient recruitment and screening in a Phase 2 study of NYX-2925 in patients with painful diabetic peripheral neuropathy (DPN).

Chinook Therapeutics, Inc. announced that Chinook management is scheduled to participate in presentations at the following upcoming virtual investor conferences: